Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Eui Gwon HwangEun-Ae JungJeong-Ju YooSang Gyune KimYoung Seok KimPublished in: Hepatology international (2023)
TAF continues to worsen lipid profiles including LDL-c, TC, and TG after 6 months of use compared to the other NAs.